Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.63 USD | -0.96% | -4.96% | +52.25% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company sustains low margins.
- The group shows a rather high level of debt in proportion to its EBITDA.
- With an expected P/E ratio at 53.42 and 24.66 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+52.25% | 714M | C | ||
-14.09% | 77.37B | B+ | ||
+18.66% | 8.74B | B- | ||
+23.75% | 3.67B | B- | ||
-0.42% | 3.25B | B- | ||
+18.07% | 1.73B | - | ||
-16.99% | 1.38B | B | ||
-0.39% | 1.31B | - | ||
-26.05% | 1.24B | C- | ||
-17.86% | 1.07B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PAHC Stock
- Ratings Phibro Animal Health Corporation